From Novartis to Not Breathing: Justice in a Jar - Examining Medicine
I’ve become interested in Novartis. It has to do with the off-label marketing of Trileptal, an epilepsy drug, for which they were fined a princely $423,000,000 in 2010. They were busted, and to avoid being treated like lesser criminals, they agreed to fork over some cash. $423M is a lot of money, but none of it went to the victims who took drugs that either failed to make them better, or actively made them worse. Life-wrecking and even death were possibilities, but the victims don’t figure into the story. In a sense, princely sums don’t either. Novartis is a very wealthy